Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.31 |
| ▸ | PTPRC | P08575 | 1/20 | 0.30 |
| ▸ | PTPRF | P10586 | 1/20 | 0.30 |
| ▸ | CDC25A | P30304 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
| ▸ | CDC25C | P30307 | 1/20 | 0.30 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1168115 | 0.84 | PTGS2 (0.41) | PTGS2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1168997 | 0.83 | MAPK14 (0.54) | PTGS2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1168674 | 0.83 | PTPN1 (0.46) | PTGS2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1168077 | 0.82 | MAPK11 (0.52) | PTGS2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1167886 | 0.82 | PTGS2 (0.39) | PTGS2MAPK13MAPK12MAPK11MAPK14 | |
| Dimethylamine SCHEMBL1167887 | 0.80 | PTGS2 (0.49) | PTGS2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1167805 | 0.80 | KMT2A (0.41) | PTGS2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL12342089 | 0.78 | PAX8 (0.41) | PTGS2 | |
| SCHEMBL1168166 | 0.78 | PTGS2 (0.41) | PTGS2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1168381 | 0.78 | PTGS2 (0.41) | PTGS2MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289483-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-8269017-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110059893-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2011-03-10 | — | — | US | disclosed |
| US-7884094-B2 | antiproliferative agents such as 2-amino-N-(2-methoxy-5-[3- (3,4,5-trimethoxy-phenyl)- isoxazol-4-yl)-phenyl)-3- phenylpropanamide, that inhibit tubulin polymerization and/or target vasculature, usefeul for the treatment of cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2011-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289483-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS2 3488/4885MAPK13 769/4885MAPK12 1264/4885 |
| US-20110059893-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS2 3488/4885MAPK13 769/4885MAPK12 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.